3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms, Castration-Resistant
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Endometrial Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Lymphoid Interstitial Pneumonia
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Selected Subjects With Advanced Solid Tumors
1
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Docetaxel
×
30 days
×
Clear all
NCT06551324
2026-05-05
MEVPRO-1
Pfizer
Phase 3
Active not recruiting
600 enrolled